Usha Ravi

Usha Ravi

Auto-generated profile, based on publicly available information

Usha Ravi

Tulare Pediatric Group, Pediatric Associates, Tulare, CA, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Obesity Pillars
Verified
Journal Article
Open access
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Pallavi ShirsatPallavi Shirsat
Pallavi Shirsat
KSKunal Sonavane
Kunal Sonavane
SPSaketh Parsi
Saketh Parsi
URUsha Ravi
Usha Ravi
SRSarah Ro
Sarah Ro
Ultra-processed foods (UPFs) have become increasingly incorporated into pediatric diets, accounting for approximately 67 % of the total energy consumption in United States (US) children. Manufactured through industrial processing and enriched with excess sugars, unhealthy fats, and sodium, while lacking essential nutrients, UPFs present a substantial public health concern. We aimed to conduct a comprehensive review of the impact of UPFs on pediatric health. We reviewed the effects of UPF on pediatric health using data from observational studies, systematic reviews, and policy reports. Our review explored the social, environmental, and economic drivers of UPF consumption, associated health consequences, and proposed mitigation strategies. We also examined National Health and Nutrition Examination Survey (NHANES) data, the 2025 US Dietary Guidelines Advisory Committee’s (USDA) report, and the Make America Healthy Again (MAHA) commission findings. UPF intake has dramatically increased during early childhood, with toddlers and school-aged children obtaining 47 % and 59.4 % of their daily calories, respectively, from UPFs. Higher consumption is linked to pediatric obesity, cardiometabolic risks such as insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD), mental health concerns, and gut microbiome disruption. Early-life exposure to UPFs can establish unhealthy dietary patterns that persist into adulthood, raising the risk of chronic disease. Greater UPF consumption is often observed among lower-income families, highlighting a key health disparity. UPF consumption is a modifiable risk factor for non-communicable diseases in children. Addressing it requires urgent, coordinated action at multiple levels. Strategies include UPF and sugar-sweetened beverage screening during well-child visits, policy restrictions on food marketing, clearer nutrition labeling, healthier school meals, and personalized family-centered dietary counseling. Clinicians need standardized tools and training to counsel families effectively. Policy initiatives should prioritize prevention-focused measures to protect children's health.

11 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPSaketh Parsi
Saketh Parsi
KSKunal Sonavane
Kunal Sonavane
URUsha Ravi
Usha Ravi
Pallavi ShirsatPallavi Shirsat
Pallavi Shirsat
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Rahul KashyapRahul Kashyap
Rahul Kashyap
Background/Objectives: Sodium glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated a reduction in heart failure (HF) hospitalizations in HF patients and decreased recurrence of atrial fibrillation (AF), including in those who have undergone catheter ablation (CA). The effects of SGLT2i are likely due to suppression of the renin–angiotensin–aldosterone system, reduction in oxidative stress with subsequent improvement in myocardial efficiency, and attenuation of cardiac remodeling. We aim to present the effects of SGLT2i on AF recurrence in patients who have undergone CA for AF. Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCTs) and retrospective studies evaluating the effect of SGLT2i on AF recurrence following CA compared with non-SGLT2i. The primary outcome was the recurrence of AF by the final follow-up reported in each study. Secondary outcomes include AF recurrence by the first follow-up within 12 to 24 months and follow-up intervals (6, 12, 18, 24, and 36 to 42 months) post-ablation, multivariate risk of AF recurrence, and the effect on left atrial diameter (LAD) (less than 45 mm vs. greater than or equal to 45 mm). For risk of bias (ROB) analysis, the NIH ROB and Cochrane ROB2 tool were used. All statistical, heterogeneity, and sensitivity analyses were conducted using Cochrane Review Manager. A random-effect model was employed for all pooled statistical analyses. Results: A total of nine studies, two RCTs and seven retrospective studies, were included (N = 6874) for the primary outcome. Compared to non-SGLT2i (N = 3693), SGLT2i (N = 3181) significantly decreased AF recurrence by the final follow-up (OR = 0.62; 95% CI: 0.45–0.85; p = 0.008). For secondary outcomes, SGLT2i significantly reduced AF recurrence by the first follow-up within 12 to 24 months post-ablation (OR = 0.58; p = 0.0001) and by the different follow-up periods, 6-month (OR = 0.53; p = 0.02), 12-month (OR = 0.56; p = 0.0001), 18-month (OR = 0.55; p = 0.01), and 24-month (OR = 0.60; p = 0.12) follow-up periods. On the other hand, by 36 to 42 months, SGLT2i was associated with increased risk of AF recurrence (OR = 1.41; p = 0.004). Conclusions: We conclude that SGLT2i demonstrated a reduction in AF recurrence following CA, particularly by 12 to 18 months post-ablation.

20 November 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
URUsha Ravi
Usha Ravi
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
SPSaketh Parsi
Saketh Parsi
HPHarikrishna Choudary Ponnam
Harikrishna Choudary Ponnam
RKRahul Kashyap
Rahul Kashyap
21 st -century innovations in pediatrics have made remarkable advancements in enhancing patient care and making care accessible even in remote areas. This abstract provides a concise summary of the latest innovations in pediatrics. Recent innovations in Pediatrics include Telemedicine, where people can connect with specialists using electronic technology, helping those in remote areas access timely care. Advances in neonatal care have effectively created solutions for several conditions, thereby reducing morbidity and mortality. The use of wearable technology has shown promise in several areas, including promoting a healthy lifestyle, monitoring physiological parameters, facilitating treatment for various conditions, and post-operative monitoring. AI in diagnostics is already aiding in earlier diagnosis and triage in emergency rooms, facilitating the diagnosis of certain genetic syndromes, and enabling the earlier detection of neonatal sepsis, among other areas in pediatrics. Innovations in pediatric vaccinations, utilizing novel technology, have made vaccines less painful and led to the development of new vaccines for conditions such as RSV, one of the viruses causing respiratory distress in newborns during the winter. Mental Health care in pediatrics has helped in reducing stigma and improving access to care for behavioral health counselling for conditions like depression and anxiety, using a smartphone app. Pediatric surgery has seen substantial progress in minimally invasive procedures, which help reduce post-operative pain, minimize tissue damage, decrease recovery time, and minimize scarring. Pediatric care now emphasizes addressing social determinants of health like housing, income, emotional support, food insecurity, and stressors in a child's life, which helps in timely referrals.

1 March 2026 in AME Case Reports
Verified
Journal Article
Open access
PDF file
SSSwetang J Shah
Swetang J Shah
URUsha Ravi
Usha Ravi
ADAahna V. Dattani
Aahna V. Dattani
AKAbhishek kumar Mariswamy Mariswamy Arun Kumar
Abhishek kumar Mariswamy Mariswamy Arun Kumar
Background: Coffin-Siris syndrome (CSS) is an uncommon genetic condition that is generally associated with developmental delay, craniofacial dysmorphism, hypertrichosis, and hypoplasia or aplasia of the fifth digit. Genetic variations in genes that encode components of the SWI/SNF chromatin-remodeling complex, such as SMARCA4, are known to cause CSS with variable phenotype expression. The expanded use of genotype-first methods has contributed to the broadening of the awareness of non-classical presentations. Case Description: We present a case of a 10-year-old girl who presented for genetic evaluation because of developmental delay, anxiety with nonverbal behavioral predominance, cleft palate repair, microcephaly, and short stature. At the age of 3 months, she was diagnosed with congenital hypothyroidism and has been on constant levothyroxine. Examination physical examination showed hypertrichosis, mild craniofacial dysmorphism, and benign joint hypermobility, intact fifth digits and nails. A heterozygous variant in SMARCA4 was identified using trio exome sequencing (c.3315G>T) which revealed a de novo heterozygous variant. A variant of uncertain significance (VUS) in AP1S2 was also identified. Past cytogenetic and molecular testing had eliminated other genetic causes of syndromic developmental delay. The multidisciplinary management incorporated surgery revision of cleft palate repair, endocrine treatment, pharmacologic treatment of anxiety, behavioral treatment, and educational assistance. Conclusions: The case presents a SMARCA4-associated phenotype of the CSS with intact fifth digits and with congenital hypothyroidism. This association has not been described in the literature to our knowledge. The findings reinforce the significance of genetic testing in children with complex patterns of development even without the traditional physical manifestations and propose that endocrine features can be considered further in SMARCA4-related CSS.